THE CORPORATE LIBRARY

Related Party Transactions and Outside Related Director Information

Pharmaceutical Product Development, Inc. (PPDI)

4/6/2006 Proxy Information

John A. McNeill, Jr. served as the CompanyŐs President until 1990 and as its Chairman of the Board until July 19934

4/12/2005 Proxy Information

John A. McNeill, Jr. served as the CompanyŐs President until 1990 and as its Chairman of the Board until July 19934

4/6/2004 Proxy Information

John A. McNeill served as President of Pharmaceutical Product Development, Inc. until 1990 and as its Chairman until July 1993.

3/28/2003 Proxy Information

In October 2001, we made an investment in Apothogen, Inc., a company formed to acquire, develop and commercialize selected pharmaceutical products. Dr. Eshelman, our Chief Executive Officer, and Dr. Mario, our Chairman, also made investments in Apothogen and served as directors of Apothogen. Dr. Mario served as ApothogenŐs Chairman since its inception and became its Chief Executive Officer in 2002. We were entitled to nominate one person to serve on ApothogenŐs seven-member board of directors. Stuart Bondurant was our director on ApothogenŐs board.

In April 2002, IntraBiotics Pharmaceuticals, Inc. acquired Apothogen. Under the terms of the acquisition, Apothogen shareholders received a pre-closing cash dividend and shares of IntraBiotics common stock in exchange for their Apothogen stock. Following the acquisition, Dr. Mario became the Chairman and Chief Executive Officer of IntraBiotics and served in that capacity during 2002. Dr. Mario currently serves as Chairman of the Board of Directors of IntraBiotics. Other than Dr. Mario, no other director or executive officer of the Company serves on the board of directors or as an executive officer of IntraBiotics.

During 2002, we subleased space to Apothogen and IntraBiotics in our offices in Wilmington and Raleigh, North Carolina, and provide drug development and administrative services to both companies. In 2002, we earned rental income from Apothogen and IntraBiotics of $170,845 and income for drug development and administrative services of $227,507 and $20,543, respectively. These amounts include monies paid to us by Apothogen prior to its acquisition by IntraBiotics and by IntraBiotics following that acquisition.